MEDXZ Stock Overview
Designs, produces, and sells high-precision devices and services in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
medmix AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 10.09 |
| 52 Week High | CHF 17.34 |
| 52 Week Low | CHF 8.10 |
| Beta | 0.95 |
| 1 Month Change | 2.44% |
| 3 Month Change | -8.61% |
| 1 Year Change | -40.51% |
| 3 Year Change | -60.34% |
| 5 Year Change | n/a |
| Change since IPO | -75.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDXZ | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -3.5% | -0.5% | -0.2% |
| 1Y | -40.5% | 7.4% | 3.7% |
Return vs Industry: MEDXZ underperformed the UK Medical Equipment industry which returned 7.1% over the past year.
Return vs Market: MEDXZ underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
| MEDXZ volatility | |
|---|---|
| MEDXZ Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 3.3% |
Stable Share Price: MEDXZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: MEDXZ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1922 | 2,684 | n/a | www.medmix.swiss |
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through Healthcare; and Consumer and Industrial segments. The company offers dental products, including mixing tips and cartridges for various applications, such as prosthetics, restorations, anesthetics, and aesthetics; drug delivery devices that are used to inject fertility drugs and growth hormones; and to treat niche diabetes indications, osteoporosis, and rare diseases; and mixing and delivery devices which are used to inject bone tissue, and to apply hemostatic sealants for internal and external wound treatment during surgical procedures.
medmix AG Fundamentals Summary
| MEDXZ fundamental statistics | |
|---|---|
| Market cap | CHF 408.72m |
| Earnings (TTM) | -CHF 7.40m |
| Revenue (TTM) | CHF 483.90m |
Is MEDXZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDXZ income statement (TTM) | |
|---|---|
| Revenue | CHF 483.90m |
| Cost of Revenue | CHF 324.20m |
| Gross Profit | CHF 159.70m |
| Other Expenses | CHF 167.10m |
| Earnings | -CHF 7.40m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 23, 2025
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 33.00% |
| Net Profit Margin | -1.53% |
| Debt/Equity Ratio | 59.1% |
How did MEDXZ perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 13:10 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
medmix AG is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christoph Gretler | Credit Suisse |
| Eugen Perger | Research Partners AG |